MindWalk Q1 Earnings Call Highlights

First-quarter revenue rose 21% year over year to CAD 3.8 million , while gross margin improved to 59%. However, the net loss widened to CAD 6.1 million as sales, marketing, R&D and administrative expenses increased. MindWalk is pursuing larger, multi-year ReefIQ enterprise agreements with major pharmaceutical companies, but negotiations may take time due to security, data governance, legal and procurement reviews. Initial contracts could produce uneven, milestone-driven revenue before transitioning to recurring revenue. The company is shifting toward platform partnerships that may include upfront payments, milestones and royalties; about 80% of its commercial funnel by value uses this model. MindWalk also secured a commitment for a US$30 million revolving credit facility at a fixed 7% rate, subject to final documentation. MindWalk NASDAQ: HYFT reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model. Gross margin increased to 59% from 48% in the prior-year quarter. However, the company’s net loss from continuing operations widened to CAD 6.1 million from CAD 4.1 million, reflecting higher spending on sales, marketing, research and development, and general and administrative activities. President and Chief Executive Officer Jennifer Bath said the company is pursuing enterprise adoption of ReefIQ, which launched in June. She described the platform as a layer that converts complex, unstructured biological data into structured representations intended to help artificial intelligence models produce more actionable insights for pharmaceutical customers. Bath said MindWalk is engaged with multiple large pharmaceutical companies regarding potential enterprise deployments of ReefIQ, though she did not identify partners, contract values, or expected closing dates. “These opportunities are substantially larger than our historical LensAI recurring revenue agreements,” Bath said, adding that investors should not use prior LensAI contracts as a benchmark for the potential size or scope of ReefIQ arrangements. According to Bath, ReefIQ is designed to generate multi-year recurring revenue as customers expand their use of the platform within biological data systems and discovery workflows. The company’s existing client base includes 19 of the top 20 global pharmaceutical companies, she said. During the question-and-answer session, Bath outlined several factors affecting the pace of enterprise negotiations. These include information technology security, data governance and data residency reviews; legal and procurement negotiations for multi-year platform agreements; and defining the programs and data domains included in an initial deployment. “None of them are really about whether or not the platform works,” Bath said of the review processes. She noted that enterprise customers are bringing MindWalk into their core data infrastructure, often across multiple jurisdictions. Chief Financial Officer Scott Areglado said initial ReefIQ arrangements could create uneven revenue patterns because they may include upfront engineering work and milestone-based payments before transitioning to annual recurring revenue. “These initial ReefIQ agreements are probably going to be relatively lumpy,” Areglado said. “It really just depends on how quickly we get adoption of ReefIQ.” MindWalk is also restructuring commercial relationships with pharmaceutical customers, increasingly pursuing broader platform partnerships rather...